All IndicationsPhase 3Phase 3Phase 3Phase 3Phase 2Phase 2Phase 2Phase 2
Osteoarthritis
6
Companies
8
Drug Programs
4
Phase 3
0
Upcoming PDUFAs
Competitors
ALCOX.PA
Nicox S.A.
Naproxcinod 375 mg bid
JNJ
Johnson & Johnson
CG 5503;tapentadol
ALCOX.PA
Nicox S.A.
Naproxcinod 375 mg
ALCOX.PA
Nicox S.A.
Naproxcinod
CARA
Cara Therapeutics, Inc.
CR845 0.25 mg
VRTX
Vertex Pharmaceuticals Incorporated
VX-150
LLY
Eli Lilly and Company
LY3016859
GLPG
Galapagos NV
GLPG1972
| Company | Drug | Phase | Designations | Timeline | Trial ID |
|---|---|---|---|---|---|
| ALCOX.PA Nicox S.A. | Naproxcinod 375 mg bid | Phase 3 | — | — | — |
| JNJ Johnson & Johnson | CG 5503;tapentadol | Phase 3 | — | — | — |
| ALCOX.PA Nicox S.A. | Naproxcinod 375 mg | Phase 3 | — | — | — |
| ALCOX.PA Nicox S.A. | Naproxcinod | Phase 3 | — | — | — |
| CARA Cara Therapeutics, Inc. | CR845 0.25 mg | Phase 2 | — | — | — |
| VRTX Vertex Pharmaceuticals Incorporated | VX-150 | Phase 2 | — | — | — |
| LLY Eli Lilly and Company | LY3016859 | Phase 2 | — | — | — |
| GLPG Galapagos NV | GLPG1972 | Phase 2 | — | — | — |
Development Stage Distribution
Phase 3
4
Phase 2
4
PDUFA Timeline
No upcoming PDUFA dates for this indication.
Not financial advice
Signals are probabilistic and based on historical data — past performance doesn't guarantee future results. Do your own research.